Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
6 Months : From Apr 2019 to Oct 2019
DNA Sciences, Inc. (NASDAQ: APDN), announced today it plans to
release financial results for its fiscal 2019 second quarter ended March
31, 2019 after market close on Thursday, May 9, 2019. In conjunction
with the release, the Company has scheduled a conference call at 4:30
p.m. Eastern Time that will also be broadcast live over the Internet.
Applied DNA’s Fiscal 2019 Second Quarter Financial Results
Thursday, May 9, 2019, at 4:30 p.m. Eastern Time
Via phone by dialing +1 844-887-9402 or +1 412-317-6798 and ask to
join the Applied DNA call; via webcast.
A telephonic replay of the conference call will be available for one day
and may be accessed by calling +1 877-344-7529 or +1 412-317-0088 with
the passcode 10130964. The webcast
will be archived within the ‘Events and Presentations’ portion of the ‘Investors’
page to the company’s website.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply
chain security, anti-counterfeiting and anti-theft technology, product
genotyping and pre-clinical nucleic acid-based therapeutic drug
Applied DNA makes life real and safe by providing innovative,
molecular-based technology solutions and services that can help protect
products, brands, entire supply chains, and intellectual property of
companies, governments and consumers from theft, counterfeiting, fraud
Visit adnas.com for more information. Follow us on Twitter and LinkedIn.
Join our mailing list.
Common stock listed on NASDAQ under the symbol APDN, and warrants are
listed under the symbol APDNW.
Forward Looking Statements
The statements made by Applied DNA in this press release may be
"forward-looking" in nature within the meaning of the Private Securities
Litigation Act of 1995. Forward-looking statements describe Applied
DNA's future plans, projections, strategies and expectations, and are
based on assumptions and involve a number of risks and uncertainties,
many of which are beyond the control of Applied DNA including the
substantial doubt relating to the Company’s ability to continue as a
going concern. Actual results could differ materially from those
projected due to its history of net losses, limited financial resources,
limited market acceptance, the uncertainties inherent in research and
development, future clinical data and analysis, including whether any of
Applied DNA’s product candidates will advance further in preclinical
research or clinical trial process, including receiving clearance from
the U.S. Food and Drug Administration or equivalent foreign regulatory
agencies to conduct clinical trials and whether and when, if at all,
they will receive final approval from the U.S. FDA or equivalent foreign
regulatory agencies, shifting enforcement priorities of US federal laws
relating to cannabis, and various other factors detailed from time to
time in Applied DNA's SEC reports and filings, including our Annual
Report on Form 10-K filed on December 18, 2018 and our subsequent
quarterly report on 10-Q filed on February 7, 2019, and other reports we
file with the SEC, which are available at www.sec.gov.
Applied DNA undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date hereof to reflect the occurrence of
unanticipated events, unless otherwise required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005114/en/
Investor contact: Sanjay M. Hurry, LHA Investor Relations,